Scarica l'app Stockscreener
21.74
1.50%
-0.33
Dopo l'orario di chiusura:
21.75
0.01
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$22.07
Aprire:
$22.14
Volume 24 ore:
1.48M
Relative Volume:
1.56
Capitalizzazione di mercato:
$3.69B
Reddito:
-
Utile/perdita netta:
$-323.01M
Rapporto P/E:
-9.7928
EPS:
-2.22
Flusso di cassa netto:
$-272.30M
1 W Prestazione:
-5.68%
1M Prestazione:
-12.23%
6M Prestazione:
-25.21%
1 anno Prestazione:
-40.29%
Intervallo 1D:
$21.70
$22.22
Intervallo di 1 settimana:
$21.48
$23.59
Portata 52W:
$21.48
$39.55
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
21.74 | 3.69B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant (NASDAQ:IMVT) Raised to Strong-Buy at Cantor Fitzgerald - MarketBeat
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Insider Monkey
12 Stocks That Will Double in 2025 - Insider Monkey
Immunovant registers shares for selling stockholders - MSN
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock - MSN
Immunovant CTO Jay Stout sells $51,780 in stock - MSN
Immunovant stock hits 52-week low at $22.39 amid market challenges - MSN
Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Insider Selling - Defense World
Immunovant stock hits 52-week low at $22.39 amid market challenges By Investing.com - Investing.com South Africa
Immunovant (NASDAQ:IMVT) Sets New 52-Week Low Following Insider Selling - MarketBeat
Immunovant (NASDAQ:IMVT) vs. Genfit (NASDAQ:GNFT) Head to Head Analysis - Defense World
Immunovant registers shares for selling stockholders By Investing.com - Investing.com Australia
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 2,657 Shares of Stock - MarketBeat
Jay S. Stout Sells 2,195 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant's chief medical officer Michael Geffner sells $62,678 in stock By Investing.com - Investing.com Canada
Immunovant CTO Jay Stout sells $51,780 in stock By Investing.com - Investing.com South Africa
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - The Malaysian Reserve
Guggenheim raises Immunovant stock target to $46, maintains Buy By Investing.com - Investing.com Canada
Cantor Fitzgerald Estimates Immunovant FY2026 Earnings - MarketBeat
Guggenheim raises Immunovant stock target to $46, maintains Buy - MSN
Immunovant's chief medical officer sells $56,782 in stock - MSN
Immunovant CFO Eva Renee Barnett sells $54,756 in stock - MSN
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Peter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in Stock - MarketBeat
Immunovant CEO Peter Salzmann sells $208,899 in stock By Investing.com - Investing.com Canada
Immunovant's chief medical officer sells $56,782 in stock By Investing.com - Investing.com Australia
Immunovant CFO Eva Renee Barnett sells $54,756 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Bank of America Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - MarketBeat
JPMorgan Chase & Co. Lowers Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
JPMorgan Chase & Co. Sells 28,586 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.22 Average Price Target from Analysts - Defense World
How to Take Advantage of moves in (IMVT) - Stock Traders Daily
Insider Buying: Immunovant, Inc. (NASDAQ:IMVT) Director Buys 16,845,010 Shares of Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):